RXI Pharma (RXII) Plans Securities Offering in the Near Future
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
RXi Pharmaceuticals Corporation (NASDAQ: RXII) announced today that it plans to conduct a securities offering in the near future. RXi plans to use the net proceeds from the offering to enable the smooth integration of MirImmune Inc. into RXi in the event that RXi exercises its option to acquire MirImmune Inc. and the timely development of RXi's current pipeline, as well as sd-rxRNA in cell therapy.
This announcement is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933. As required by Rule 135, this press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RXi Pharmaceuticals to Webcast Third Quarter 2016 Financial Results on Thursday, November 10, 2016
- Aeterna Zentaris (AEZS) Announces $7.56M Common Stock, Warrants Registered Direct Offering
- LendingTree Reports Q3 2016 Results
Create E-mail Alert Related CategoriesEquity Offerings
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!